RYTMNGMHealthcare·Biotechnology#43 in industry

Rhythm Pharmaceuticals, Inc.

Reports in 8d· 2026-05-05

-19.3% · 90d

$85.20

-0.50 (-0.58%)

After-Hours $85.20(+0.00)

News

(1)

April 2026

Apr 3, 20263 weeks ago8-KHealthcare

RHYTHM PHARMACEUTICALS, INC. — 8-K Filing

RYTMRHYTHM PHARMACEUTICALS, INC.

# 🧾 What This Document Is This is a Form 8-K, which is a report U.S. companies file with the SEC to announce major, unscheduled events that shareholders should know about. Today's announcement is all about a change in the company's leadership team—specifically on its Board of Directors. # 🏢 What

Read summaryView on SEC EDGAR

Key Data

Market Cap$5.82B

Open$85.50

Prev Close$85.70

Day Range$84.88 – $87.66

52W Range$55.31 – $122.20

Volume341,858

P/E (TTM)—

EPS$-3.11

Dividend Yield—

Beta2.14

Profit Margin-103.57%

Revenue Growth36.90%

Price Target$137.67(+61.6%)

Next Earnings2026-05-05(8d)

Analyst Ratings

Strong Buy16 analysts

Buy 15Hold 1Sell 0

About

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Healthcare · Biotechnology

414 employees

rhythmtx.com